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Mdivi-1, a mitochondrial fission inhibitor,
modulates T helper cells and suppresses
the development of experimental
autoimmune encephalomyelitis
Yan-Hua Li1,2†, Fang Xu3†, Rodolfo Thome1, Min-Fang Guo2, Man-Luan Sun2, Guo-Bin Song2, Rui-lan Li2, Zhi Chai3,
Bogoljub Ciric1, A. M. Rostami1, Mark Curtis4, Cun-Gen Ma2,3* and Guang-Xian Zhang1*
Abstract
Background: Unrestrained activation of Th1 and Th17 cells is associated with the pathogenesis of multiple sclerosis
and its animal model, experimental autoimmune encephalomyelitis (EAE). While inactivation of dynamin-related protein 1
(Drp1), a GTPase that regulates mitochondrial fission, can reduce EAE severity by protecting myelin from demyelination,
its effect on immune responses in EAE has not yet been studied.
Methods: We investigated the effect of Mdivi-1, a small molecule inhibitor of Drp1, on EAE. Clinical scores, inflammation,
demyelination and Drp1 activation in the central nervous system (CNS), and T cell responses in both CNS and periphery
were determined.
Results: Mdivi-1 effectively suppressed EAE severity by reducing demyelination and cellular infiltration in the CNS. Mdivi-1
treatment decreased the phosphorylation of Drp1 (ser616) on CD4+ T cells, reduced the numbers of Th1 and Th17 cells,
and increased Foxp3+ regulatory T cells in the CNS. Moreover, Mdivi-1 treatment effectively inhibited IFN-γ+, IL-17+, and
GM-CSF+ CD4+ T cells, while it induced CD4+ Foxp3+ regulatory T cells in splenocytes by flow cytometry.
Conclusions: Together, our results demonstrate that Mdivi-1 has therapeutic potential in EAE by modulating the balance
between Th1/Th17 and regulatory T cells.
Keywords: Experimental autoimmune encephalomyelitis, Dynamin-related protein 1, Mdivi-1, T cells
Introduction
Multiple sclerosis (MS) is an immune-mediated chronic
demyelinating disease of the central nervous system
(CNS), characterized by inflammatory infiltrates, myelin
loss, and axonal damage [17, 23]. Experimental auto-
immune encephalomyelitis (EAE) is an animal model of
MS that is often used to study the pathogenesis and thera-
peutics of the disease. EAE develops as myelin-specific
CD4+ T cells penetrate into the CNS and secrete cytokines
and other inflammatory mediators, which, in turn, recruit
peripheral leukocytes that promote damage to the myelin
sheaths [27].
In the pathogenesis of MS, two mutually complementary
processes can be identified: autoimmune inflammation is
more pronounced at the initial stages of the disease, while
axonal neurodegeneration is observed in advanced disease
[11]. Given that mitochondrial dysfunction is a major factor
in the neurodegenerative process [20], targeting mitochon-
drial functions may be a promising therapeutic approach
[12, 32]. Indeed, treatment with P110, a peptide inhibitor
that targets dynamin-related protein 1 (Drp1), protects
myelin in cuprizone-induced demyelination and EAE
models by blocking Drp1 localization to the mitochondria,
thus reducing mitochondrial fragmentation, oligodendroglial
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cell death, and microglia activation [16]. Mitochondrial
division inhibitor-1 (Mdivi-1), similar to P110, is a highly
efficient small molecule that selectively inhibits Drp1 self-as-
sembly and GTPase activity, thus protecting target cells
from oxidative stress and caspase-dependent and -independ-
ent apoptosis [10, 12, 26, 33, 35]. Mdivi-1 can cross the
blood-brain barrier (BBB) and has a half-life of 12 h [5, 12].
Importantly, small molecule inhibitors are safer and less
costly than peptide inhibitors. However, the effect of Mdivi-
1 on immune responses in EAE remains to be determined.
In this study, we demonstrate that Mdivi-1 markedly
inhibited Drp1 activation in CD4+ T cells, and sup-
pressed EAE by modulating the infiltration of Th1 and
Th17 cells while increasing the proportion of Foxp3+
Treg cells in the CNS. Mdivi-1 treatment also inhibited
the expression of proinflammatory cytokines and upreg-
ulated the numbers of FoxP3+ Tregs in the periphery.
Overall, our data show that Mdivi-1 has therapeutic po-




Female C57BL/6 mice, 8–10 weeks of age, were purchased
directly from the Jackson Laboratory (Bar Harbor, ME,
USA). Experimental protocols were guided by the Institu-
tional Animal Care and Use Committees of Thomas
Jefferson University and Shanxi Datong University. All
mice were bred in pathogen-free cages, under constant
temperature, with free access to food throughout the ex-
perimental process.
Induction and clinical evaluation of EAE
EAE was induced by subcutaneously immunizing mice
with 200 μL of an emulsion containing 200 μg of myelin
oligodendrocyte glycoprotein peptide 35–55 (MOG35–55
peptide, MEVGWYRSPFSRVVHLYRNGK, Genscript,
NJ, USA) and an equal volume of Freund’s Complete ad-
juvant (Sigma-Aldrich, St. Louis, MO, USA) supple-
mented with 10 mg/mL of heat-killed Mycobacterium
tuberculosis H37Ra (Difco, Detroit, MI, USA). Mice also
received 200 ng of pertussis toxin (List Biologic Labora-
tories, Inc., Campbell, CA, USA) on days 0 and 2 post
immunization (p.i.). Onset and progression of EAE signs
were monitored daily on a 0–5 scale, where 0 = healthy,
1 = limp tail, 2 = hind limb weakness, 3 = paralysis of
hind limb, 4 = tetraparalysis, and 5 =moribund/death. Fi-
nally, for each animal, we determined the time to disease
onset, incidence rate, peak score, and cumulative disease
score (sum of daily scores from disease onset to day 28).
Mdivi-1 treatment
Mice were randomly divided into two groups: Mdivi-1-
treated and DMSO-treated as control (n = 15 each group).
Mdivi-1 was dissolved in dimethyl sulfoxide (0.1%
DMSO). Mdivi-1 (25mg/kg) or 0.1% DMSO was given in-
traperitoneally from day 3 p.i., until day 27 p.i.
Histology and immunohistochemistry
In the mouse EAE model, the accumulation of autoreac-
tive T cells was much greater in the dorsal blood vessels of
the fifth lumbar spinal cord than in the ventral ones, sug-
gesting dorsal blood vessels of the fifth spinal cord may be
the gate for autoreactive T cells to enter the CNS [1, 15].
Lumbar spinal cords were therefore harvested after mice
had been extensively perfused with saline and 4% PFA,
and then fixed for 4 h in 2% PFA prior to OCT or paraffin
embedding for pathological assessment. Consecutive 4 μm
or 10 μm sections were taken, and Luxol Fast Blue (LFB)
staining and hematoxylin and eosin (H&E) stained slices
were analyzed in a blind fashion to assess basic histo-
pathological changes. For immunohistochemistry [13],
sections were preincubated for 2 h with the blocking buf-
fer (1% BSA in PBS) and then incubated with one of the
following polyclonal and monoclonal primary antibodies:
anti-myelin basic protein (Millipore, Billericay, MA), anti-
CD4, anti-IFN-γ, anti-IL-17 (BD, NJ, USA), anti-IL-10,
and anti-pDrp1 (ser616) (Abcam, Cambridge, UK). As a
negative control, additional sections were treated similarly,
but the primary antibodies were omitted. Results were ob-
served under confocal laser scanning microscope (CLSM,
Olympus, Tokyo, Japan) using FV1200 software in a
blinded fashion. Image-Pro Plus 6 was used to quantify
staining areas and the number of infiltrating cells. Histo-
logical analyses were performed on at least two sections
per mouse, and nine mice per group were analyzed.
Preparation of mononuclear cells from spleen and the
CNS
Mice were euthanized and perfused with cold saline at day
21 or 28 p.i. Spleens, brains, and spinal cords were collected
in Iscove’s modified Dulbecco’s medium (IMDM, Thermo
Fisher Scientific, Carlsbad, CA) supplemented with 10%
heat-inactivated fetal bovine serum (Thermo Fisher Scien-
tific), 100 U penicillin, 10 μg/mL streptomycin, 0.3 mg/mL
L-glutamine, and 55 μM 2-mercaptoethanol. Single mono-
nuclear cell (MNC) suspensions were prepared as described
[28]. Spleens were mechanically disrupted through a 70-μm
cell strainer, treated with RBC lysis buffer (Biolegend, CA,
USA) for 1 min, and washed in IMDM. Brains and spinal
cords were cut into pieces with scissors and enzymatically
digested with 700 μg/mL Liberase TL (Roche, Nutley, NJ)
for 30 min at 37 °C, filtered with a 70-μm cell strainer, and
washed with IMDM. CNS MNCs were enriched by centri-
fuging cells in a 70/30% percoll gradient (Sigma-Aldrich,
USA) for 20 min at 450 g.
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Flow cytometry analysis
One million MNCs were moved to FACS tubes, stimu-
lated with PMA (50 ng/mL) and ionomycin (500 ng/mL)
in the presence of GolgiPlug (1 μg/106 cells, Sigma-Al-
drich) for 4 h at 37 °C. For surface-maker staining, cells
were incubated with fluorochrome-labeled Abs to CD4
(Clone GK1.5, BD Biosciences) in a final volume of
100 μL PBS at 4 °C for 20 min. For intracellular staining,
cells were washed, fixed, and permeabilized using Fix
and Perm cell permeabilization reagents (eBioscience).
Fig. 1 Mdivi-1 ameliorates the severity of EAE and demyelination. C57BL/6 mice were immunized with MOG35–55, Mdivi-1 (25 mg/kg) was given
intraperitoneally, and 0.1% DMSO was established as control (n = 15 each group) in a similar manner on day 3 p.i., until day 27 p.i. Lumbar regions of
spinal cords were harvested for LFB staining and immunostaining of MBP. a Clinical score of EAE mice, and b representative microphotographs for
demyelination (Luxol Fast Blue staining and MBP immunostaining) and quantitative analysis of demyelination of whole spinal cord white matter
lesions. Data represent mean ± SEM (n = 7–9 each group). *P < 0.05; **P < 0.01; ***P < 0.001. One representative of two experiments is shown
Table 1 Clinical evaluation of mice with EAE
Group Disease onset Disease incidence (%) Peak score Cumulative disease score
DMSO (n = 15) 13.1 ± 0.7 95% 3.6 ± 0.4 42.9 ± 5.5
Mdivi-1 (n = 15) 13.4 ± 0.6 65%* 1.8 ± 0.5* 16.4 ± 5.6**
Mdivi-1 was intraperitoneally administered at 25 mg/kg daily starting from day 3 p.i. Disease onset was defined as the first day of 2 consecutive days with a
clinical score. Disease incidence was defined as the percentage of mice that displayed any clinical signs of disease. Cumulative disease scores were calculated as
the sum of all daily scores of each individual mouse divided by the number of mice in each group. *P < 0.05, **P < 0.01, DMSO vs. Mdivi-1-treated mice
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Intracellular cytokines were stained with Abs against IL-
10 (Clone JES5-16E3, BD Biosciences), IL-17 (Clone
TC11-18H10.1, Biolegend), IFN-γ (XMG 1.2, BD Biosci-
ences), or Foxp3 (Clone FJK-16 s, eBioscience) in a final
volume of 100 μL permeable solution for overnight at
4 °C. Samples were acquired on a FACSAria (BD Biosci-
ences, USA). Instrument setup and calibration were
performed daily using Cytometer Setup and Tracking
beads (BD Biosciences, USA). In addition, cytometer
configuration and compensation were set according to
BD Biosciences recommendations. Data were analyzed
with FlowJo Software (Treestar, Ashland, OR).
Cytokine measurement by ELISA
Splenocytes were cultivated at a density of 1.0 × 106
cells/mL in complete IMDM with or without 25 μg/
mL MOG35–55 for 72 h. After the incubation period,
supernatants were collected and assayed for IL-4, IL-
5, IL-17, IFN-γ, GM-CSF, and IL-10 using ELISA kit
(R&D System, Minneapolis, MN, USA). Determina-
tions were performed in duplicate and results were
expressed as pg/mL.
Statistical analysis
Graphad Prism software (Cabit Information Technology,
Shanghai, China) was used for statistical analysis. Experi-
mental data were shown as mean ± SEM. Clinical mean
score was analyzed by non-parametric Kruskal-Wallis
test to determine whether an overall statistically signifi-
cant change existed before using Mann-Whitney U test
to analyze the difference between any two groups. Com-
parisons between two groups were carried out with Stu-
dent’s t test. When comparing multiple groups, data
were analyzed with one-way ANOVA with Tukey’s
Fig. 2 Mdivi-1 suppressed spinal cord inflammation. Lumbar regions of spinal cords were harvested from mice described in Fig. 1a for hematoxylin and
eosin (H&E) staining and immunostaining of CD4 on day 28 p.i. a Representative microphotographs and quantitative analysis for H&E staining; b infiltration
of CD4+ T cells in spinal cords (green) and quantitative analysis of spinal cords; and c mononuclear cells (MNCs) were isolated from the brain and spinal
cord on day 28 p.i., then analyzed with flow cytometry. Mononuclear cells were gated and percentages of CD4+ T cells in that gate were quantitatively
analyzed. Data represent mean ± SEM (n= 5–8 each group). *P< 0.05; ***P< 0.001. One representative of two experiments is shown
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multiple comparisons test. A criterion of P < 0.05 was
considered to be significant.
Results
Mdivi-1 alleviated the severity of EAE
To investigate if Mdivi-1 suppresses EAE, mice were im-
munized with MOG35–55 peptide and treated with daily
doses of Mdivi-1 (25 mg/kg) or vehicle (DMSO 0.1%)
from day 3 p.i. until day 27 p.i. Our results show that
EAE developed in DMSO and Mdivi-1-treated mice at
day ~ 13 p.i. to a similar extent (Fig. 1a and Table 1).
However, disease incidence, peak score, and cumulative
scores were reduced in Mdivi-1-treated compared with
DMSO-treated mice (Table 1). Mdivi-1-treated mice also
presented lower demyelination evaluated by Luxol Fast
Blue staining and MBP immunostaining compared with
DMSO-treated mice (Fig. 1b). These results show that,
although Mdivi-1 does not influence the onset of EAE,
overall demyelination and clinical development were re-
duced in treated mice compared with controls.
Mdivi-1 reduced cellular infiltrates in the spinal cord of
EAE mice
To investigate if the amelioration of EAE observed in
Mdivi-1-treated mice correlated with a decrease in CNS
inflammation, we analyzed the infiltration of peripheral
cells in the CNS. We found that in the spinal cord of
Mdivi-1-treated mice, total inflammatory infiltration foci
were notably decreased compared to DMSO-treated
mice, as shown by H&E staining (Fig. 2a). We then ana-
lyzed the proportion of CD4+ T cells by immunostaining
and flow cytometry. Results showed that CD4+ T cells
could barely be detected in the spinal cords of EAE mice
injected with Mdivi-1; a large number of CD4+ T cells
were found in EAE mice treated with DMSO (Fig. 2b, c).
Mdivi-1 inhibited phosphorylation of Drp1 (p-Drp1;
ser616) in CD4+ T cells
Given that Mdivi-1 prevents Drp1 phosphorylation [26],
we determined its effect on Drp1 phosphorylation in T
cells by co-immunostaining of ser616 with CD4 in spinal
cord tissues of EAE mice. Our results showed high
number of ser616+CD4+ T cells in spinal cord of
DMSO-treated control EAE mice, and its level was
markedly decreased in Mdivi-1-treated mice (Fig. 3).
Mdivi-1 inhibited Th1 and Th17 cells but upregulated IL-
10+ T cells and Treg cells in the CNS
Based on microenvironmental cues, naive T cells differen-
tiate into Th1 and Th17 cells that are fundamental to EAE
development [22]. To test if Mdivi-1 influences these pro-
inflammatory T cell subsets in the CNS, we analyzed the
frequency of IFN-γ+, IL-17+, and CD4+ T cells in Mdivi-1-
treated mice and compared it with that in DMSO-treated
mice. Our results showed that Mdivi-1 treatment reduced
both absolute and relative numbers of IFN-γ-producing
Th1 cells and IL-17-producing Th17 cells compared with
DMSO-treated mice (Fig. 4a–d). We then investigated
whether the mechanism of Mdivi-1 action included favor-
ing Treg cells and IL-10 production over Th1/Th17 cells
in the CNS, and found that the proportion of Treg cells
and IL-10+CD4+ cells was significantly increased in the
brain and spinal cords of Mdivi-1-treated mice compared
with DMSO-treated mice (Fig. 5a–c).
Mdivi-1 treatment inhibited Th1/Th17 cells and induced
Treg cells in the periphery
We explored whether Mdivi-1 could modulate T cells in
the periphery. We found that the percentages of CD4+ T
cells were similar in the splenocytes of two groups of mice
and the percentages of IFN-γ+ IL-17+, and GM-CSF+ cells
Fig. 3 Mdivi-1 inhibited phosphorylation of Drp1 (p-Drp1; ser616) in CD4+ T cells. Lumbar regions of spinal cords were harvested for immunostaining of
CD4, p-Drp1 (ser616) on day 28 p.i. Representative microphotographs for CD4+ser616+ cells in spinal cords and quantitative analysis of area (polygon) of
CD4+ser616+ cells in spinal cords. Data represent mean ± SEM (n= 5–8 each group). **P< 0.001. One representative of two experiments is shown
Li et al. Journal of Neuroinflammation          (2019) 16:149 Page 5 of 11
in gated CD4+ T cells (Fig. 6a) were markedly decreased in
Mdivi-1-treated mice compared with DMSO-treated mice
(Fig. 6b). Conversely, frequencies of CD4+Foxp3+ Treg
cells and CD4+IL-10+ T cells were significantly higher in
Mdivi-1-treated mice than in those of controls (Fig. 6c).
Of note is that the frequency of IL-10-producing cells is
higher than Treg (CD4+Foxp3+) in both Mdivi-1- and
DMSO-treated mice. These Foxp3− IL-10-producing T
cells (6–7%) are most likely type 1 regulatory T cells (Tr1)
[7]. This population, although relatively small, will be fur-
ther investigated in future studies.
Mdivi-1 suppressed auto-antigen-induced Th1/Th17
responses
Next, we analyzed whether the autoantigen-induced im-
mune response was modulated by Mdivi-1. Splenocytes
Fig. 4 Mdivi-1 reduced the number and percentage of Th1 and Th17 cells in the CNS. Lumbar regions of spinal cords were harvested from mice
described in Fig. 1a. a Representative microphotographs for infiltration of CD4+ IFN-γ+ cells in spinal cords and quantitative analysis of number of
CD4+ IFN-γ+ cells in spinal cords. b Flow cytometry analysis of CD4+ IFN-γ+ cells in brain and spinal cords and quantitative analysis of percentage
of IFN-γ+ cells in gated CD4+ cells described in Fig. 2c. c Representative microphotographs for infiltration of CD4+IL-17+ cells in spinal cords and
quantitative analysis of number of IL-17+ cells in spinal cords. d Flow cytometry analysis of CD4+ IL-17+ cells in brain and spinal cords and
quantitative analysis of percentage of IL-17+ cells in gated CD4+ cells described in Fig. 2c. Data represent mean ± SEM (n = 5–8 each group). *P <
0.05, ***P < 0.001. One representative of two experiments is shown
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from Mdivi-1- and DMSO-treated mice were cultivated
with or without MOG35–55 for 72 h and the superna-
tants were assayed for production of IFN-γ, IL-17, GM-
CSF, IL-5, IL-4, and IL-10. Our results showed that cells
from Mdivi-1-treated mice produced significantly lower
amounts of IFN-γ, IL-17, and GM-CSF; however, pro-
duction of IL-4, IL-5, and IL-10 was not significantly
changed compared with that from the DMSO-treated
group (Fig. 7).
Discussion
Our present study for the first time provides evidence
that treatment with Mdivi-1, a small molecule inhibitor
of Drp1, significantly reduced EAE clinical severity by
suppressing inflammation and demyelination in the
CNS. Mdivi-1 inhibited the level of p-Drp1 (ser 616) in
CD4+ T cells, inhibited Th1 and Th17 T cells but upreg-
ulated Foxp3+ Tregs in the CNS and periphery of EAE
mice.
Fig. 5 Mdivi-1 increases Treg cell number in the CNS. Lumbar regions of spinal cords were harvested from mice described in Fig. 1a. a
Representative microphotographs for infiltration of CD4+ IL-10+ cells in spinal cords and absolute and/or relative quantitative analysis of number
of CD4+ IL-10+ and CD4− IL-10+ cells in spinal cord slices. b Flow cytometry analysis of CD4+Foxp3+ cells in brain and spinal cords and
quantitative analysis of percentage of Foxp3+ cells in gated CD4+ cells described in Fig. 2c. Data represent mean ± SEM (n = 5–8 each group).
*P < 0.05; **P < 0.005. One representative of two experiments is shown
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Fig. 6 (See legend on next page.)
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The proper functioning of mitochondria in T cells is crit-
ical for their activation, differentiation, and function [19]. T
cell plasticity is influenced by their metabolism and ATP
demand, where mitochondrial morphology plays an im-
portant role [14]. Recent research has shown cellular me-
tabolism critically influences T cell differentiation and
function, and emerges as a key target for therapy in the
treatment of autoimmune diseases, infections, and cancer
[19]. The different T cell subsets require distinct metabolic
programming. For example, effector T cells have high ener-
getic demands and require aerobic glycolysis [30], and the
TCA cycle is also necessary for effector T cell function [31].
Conversely, memory and naïve T cells consume less energy
and rely on fatty acid oxidation and oxidative phosphoryl-
ation [30]. Likewise, increased glycolysis and mitochondrial
production of reactive oxygen species (ROS) also boost T
cell calcium signaling [8] and specific effector functions, in-
cluding expression of pivotal cytokines in activated CD4 T
cells [9, 21]. Interestingly, although effector T cells rely on
glycolysis and the TCA cycle for their metabolic supply,
Treg cells require fatty acid oxidation to meet their meta-
bolic needs [19]. The regulation of T cell differentiation and
function by metabolism is closely linked to the role of the
mTOR signaling pathway. mTOR is directly involved in
fatty acid synthesis, promotion of aerobic glycolysis, and
mitochondrial biogenesis and thus is very active in effector
T cells, whereas blockage of mTOR facilitates the develop-
ment of Treg cells [29]. In addition, the metabolism of
amino acids, glutamine, for example, induces Th17 but
limits Th1 and CTL effector cell differentiation [9].
Our results show that Mdivi-1 reduced the number of in-
flammatory cells while increasing the number of Treg cells
in the CNS of EAE mice. How Mdivi-1 affects Th cell dif-
ferentiation in EAE is unknown. Given that mitochondrial
dynamics are associated with mitochondrial metabolism,
bioenergetic demand, and cellular physiology [4, 6, 18], it
would be reasonable to expect that mitochondrial morph-
ology and the metabolic pathway regulate T cell subset dif-
ferentiation and function [4]. Drp1, a main component of
the mitochondrial fission machinery, is a major player in
mitochondrial morphology and metabolism. Drp1 inhib-
ition has been observed in T memory cells (TM) where
mitochondria are fused together and have an elongated
form; conversely, effector T cells (TE) have fragmented
mitochondria due to an upregulation of Drp1 phosphoryl-
ation [14]. Further, Drp1-dependent mitochondrial fission
(See figure on previous page.)
Fig. 6 Mdivi-1 modulates systemic immune responses in EAE. Splenocytes of mice described in Fig. 1a were isolated on day 28 p.i., then directly
analyzed with flow cytometry. a Mononuclear cells were gated and percentages of CD4+ T cells in that gate were quantitatively analyzed. b
Percentage of Th1 cells in gated CD4+ T cells (CD4+ IFN-γ+), Th17 cells (CD4+ IL-17+), c Th2 cells (CD4+ IL-4+), Treg cells (CD4+IL-10+,
CD4+Foxp3+). Data represent mean ± SEM (n = 5–8 each group). *P < 0.05. One representative of two experiments is shown
Fig. 7 Splenocytes from Mdivi-1 treated mice did not respond to MOG35–55. Splenocytes of mice described in Fig. 1a were isolated on day 28
p.i. and cultured in complete IMDM with or without Ag (50 μg/mL MOG35–55) for 72 h. After the incubation period, supernatants were collected
and assayed for cytokine production using ELISA kits. Data represent mean ± SEM (n = 5–8 each group). ***P < 0.001. One representative of two
experiments is shown
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correlates with an increase in ROS production, CD95L-
dependent, activation-induced cell death (ACID), and
cytokine production in T cells, and inhibition of Drp1 in
PHA- or anti-CD3-stimulated T cells results in reduced
ROS, ACID, and cytokine production [24]. Absence or di-
minished phosphorylation of Drp1 depolarizes mitochon-
dria and reduces the threshold for T cell activation [2].
During T cell/APC cognate interactions, Drp1 controls T
cell activation through modulating mitochondria position-
ing at the immune synapse [2]. Mdivi-1, through blockade
of Drp1, impairs mitochondrial redistribution, which results
in failure of T cell immune synapses to organize. Mdivi-1
promotes the differentiation of memory-like T cells from
TE cells through enhancing mitochondrial fusion [4]. In our
study, we observed increased Drp1 phosphorylation in
CD4+ T cells in EAE, an animal model of human MS, and
this phosphorylation was significantly inhibited after Mdivi-
1 treatment. These results provide evidence that pDrp1
inhibition may be one of the mechanisms underlying the ef-
fect of Mdivi-1 in inhibiting Th1/Th17 cells but stimulated
Treg cells in EAE mice. Of note is that splenocytes of
Mdivi-1-treated mice produced significantly lower amounts
of IFN-γ, IL-17, and GM-CSF upon MOG35–55 peptide
stimulation, but production of IL-4, IL-5, and IL-10 was
not significantly changed. These results suggest that inhibit-
ing myelin-reactive proinflammatory immune responses,
but not inducing immunomodulatory cytokine production
in the periphery, could be a major mechanism underlying
the effect of Mdivi-1 treatment in EAE. Further, while IL-
10 production in splenocytes remained similar, Mdivi-1
treatment significantly upregulated the percentage of
FoxP3+CD4+ Tregs. These results indicate an IL-10-inde-
pendent Treg function, which relies primarily on contact
with target cells [7].
Although Mdivi-1 is widely considered to be a Drp1
inhibitor, it may also act via multiple mechanisms inde-
pendent of Drp1 inhibition. Indeed, Mdivi-1 attenuates
mitochondrial ROS production through inhibiting mito-
chondrial complex I, without impairing Drp1 activity or
lengthening mitochondria [3]. Mdivi-1 protects against
neuronal injury independently of Drp1, however,
through modulating mitochondrial function and intra-
cellular Ca2+ signaling [25]. Mdivi-1 also protects the
BBB from leakage by decreasing its susceptibility to
MMP-9 and by the degradation of claudin-5, occludin,
and ZO-1 [34]. Therefore, further study to explore any
pDrp1 inhibition-independent mechanisms to reprogram
T cell activation, differentiation, and function, as well as
BBB function, in autoimmune diseases is warranted.
Conclusion
Our results demonstrate that Mdivi-1 has therapeutic po-
tential in EAE by modulating the balance between Th1/
Th17 and regulatory T cells. These effects, combined with
the direct neuroprotective effects of Drp1 inhibition [16],
as well as the capacity of Mdivi-1 to cross the BBB [5, 12],
indicate that Mdivi-1 may have significant potential as a
novel MS therapy in the future.
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